Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

• If you are wondering whether Viking Therapeutics at around US$33.75 is still a sensible entry or hold after its run in the spotlight, you are not alone.

• The stock has moved 10.8% over the last 7 days, 4.7% over the past month, is down 4.7% year to date, and is up 19.2% over 1 year and 206.5% over 3 years, which naturally raises questions about how much of its story is already reflected in the price.

• These moves have kept Viking Therapeutics in focus for investors looking at biotech names with meaningful past share price swings and ongoing clinical and regulatory headlines in the sector. Recent coverage has often centred…